QGEN - QIAGEN N.V.
| Previous Close | 34.51 |
| Open | 34.27 |
| Bid | 34.66 x 1200 |
| Ask | 34.75 x 800 |
| Day's Range | 34.15 - 34.76 |
| 52 Week Range | 30.64 - 39.45 |
| Volume | 501,803 |
| Avg. Volume | 1,060,979 |
| Market Cap | 7.828B |
| Beta (3Y Monthly) | 1.41 |
| PE Ratio (TTM) | 90.81 |
| EPS (TTM) | 0.38 |
| Earnings Date | Feb 1, 2019 - Feb 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 40.31 |
- GlobeNewswire•6 days ago
Recent Analysis Shows Cleveland-Cliffs, Optical Cable, Camtek, QIAGEN N.V, Value Line, and Zymeworks Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Nov. 13, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Simply Wall St.•10 days ago
With A 3.6% Return On Equity, Is QIAGEN NV (NYSE:QGEN) A Quality Stock?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On Read More...
GuruFocus.com•12 days agoVanguard Health Care Fund Buys 4 Stocks in 3rd Quarter
The Vanguard Health Care Fund (Trades, Portfolio) released its third-quarter portfolio last week, listing four new positions. Warning! GuruFocus has detected 1 Warning Sign with ELAN. Managed by Jean Hynes, the fund invests in a number of diverse health care-related stocks from around the world in order to achieve long-term capital appreciation.
- Zacks•12 days ago
Pacific Biosciences (PACB) Reports Q3 Loss, Revenues Fall Y/Y
Pacific Biosciences (PACB) is getting acquired by Illumina (ILMN) by mid-2019.
- Motley Fool•18 days ago
QIAGEN Acquires Growth
With lackluster growth, the diagnostic test and lab supplier acquired an option to get into a new diagnostic test market.
Markit•19 days agoSee what the IHS Markit Score report has to say about Qiagen NV.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Thomson Reuters StreetEvents•19 days ago
Edited Transcript of QGEN earnings conference call or presentation 30-Oct-18 1:00pm GMT
Q3 2018 Qiagen NV Earnings Call
Motley Fool•20 days agoQiagen NV (QGEN) Q3 2018 Earnings Conference Call Transcript
QGEN earnings call for the period ending September 30, 2018.
- Zacks•20 days ago
QIAGEN (QGEN) Beats Earnings and Revenue Estimates in Q3
QIAGEN's (QGEN) year-over-year revenue growth in Q3 and operating margin expansion are encouraging.
- Zacks•21 days ago
Qiagen (QGEN) Q3 Earnings Surpass Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of 6.06% and -1.11%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•21 days ago
Qiagen: 3Q Earnings Snapshot
On a per-share basis, the Venlo, Netherlands-based company said it had profit of 26 cents. Earnings, adjusted for amortization costs and restructuring costs, were 35 cents per share. The results beat Wall ...
- Business Wire•21 days ago
QIAGEN Expands Next-Generation Sequencing Portfolio with Oncology and Immuno-Oncology Panels for Research Using GeneReader NGS System and Other Platforms
Sample to Insight solutions enabling deep analysis of disease-related genomic mutations
- Business Wire•21 days ago
QIAGEN Reports Results for Third Quarter and First Nine Months of 2018
QIAGEN reports results for third quarter and first nine months of 2018
- Business Wire•21 days ago
QIAGEN Expands QIAGEN Clinical Insight Software to Support All Major Sequencing Platforms and Assay Types
Adding QCI Analyze Universal to NGS bioinformatics offering, plus immuno-oncology content and additional features in analysis and interpretation
- Zacks•28 days ago
Qiagen (QGEN) Q3 Earnings Preview: What to Look Out For
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•last month
QIAGEN Launches QIAstat-Dx Panel in Europe, Widens Suite
QIAGEN (QGEN) continues to expand test menu; latest European launch to boost portfolio and top line.
- Business Wire•last month
QIAGEN’s Next-Generation QIAstat-Dx System Delivers Fast, Cost-Effective Diagnosis of Gastrointestinal Syndromes
New gastrointestinal panel includes comprehensive viral coverage and provides Sample to Insight workflows to clinics in Europe and Australia
- Business Wire•last month
QIAGEN N.V. to Report Third Quarter and First Nine Months of 2018 Results
QIAGEN N.V. plans as previously announced to release its report on results for the third quarter 2018 on Monday, October 29 shortly after 21:00 Central European Time / 16:00 Eastern Daylight Time .
- Zacks•last month
QIAGEN Introduces New RNA-seq Library Preparation Solutions
QIAGEN (QGEN) adopts initiatives to boost the NGS portfolio.
- Business Wire•last month
QIAGEN Launches Novel RNA-Seq Library Preparation Solutions for Next-Generation Sequencing
Studies on new QIAGEN solutions for NGS are presented at ASHG as QIAseq portfolio and user base expands significantly
Markit•last monthSee what the IHS Markit Score report has to say about Qiagen NV.
Qiagen NV NYSE:QGEN
- Zacks•2 months ago
QIAGEN's FDA Nod for Expanded EGFR Test Use Widens Suite
QIAGEN (QGEN) continues to expand test menu; latest FDA approval to boost portfolio.
- Business Wire•2 months ago
QIAGEN Applauds Bold UN Plan for Tuberculosis Prevention and Care
Frankfurt Prime Standard: QIA) today applauded a commitment by world leaders attending the first-ever high-level United Nations meeting on tuberculosis (TB) to mobilize $13 billion a year by 2022 to implement prevention and care for TB, the world’s most deadly infectious disease. The heads of state meeting at the United Nations General Assembly pledged to ensure that 40 million people who are diagnosed with tuberculosis receive the care they need by the end of 2022 and agreed to provide preventive testing and treatment to 30 million people.
- Business Wire•2 months ago
QIAGEN Receives FDA Approval to Expand Use of EGFR Test in Lung Cancer
Approval allows use of therascreen® EGFR RGQ PCR Kit as a companion diagnostic for Pfizer’s VIZIMPRO® in patients with non-small cell lung cancer
- Simply Wall St.•2 months ago
How Financially Strong Is QIAGEN NV (NYSE:QGEN)?
Mid-caps stocks, like QIAGEN NV (NYSE:QGEN) with a market capitalization of US$8.50b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. Read More...
